Marshall Wace
MCRB icon

Marshall Wace’s Seres Therapeutics MCRB Stock Holding History

Marshall Wace’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
172,245
+32,706
+23% +$249K ﹤0.01% 2052
2026
Q1 		$1.24M Buy
139,539
+19,362
+16% +$227K ﹤0.01% 2032
2025
Q4 		$1.79M Sell
120,177
-5,423
-4% -$94.6K ﹤0.01% 1630
2025
Q3 		$2.42M Buy
125,600
+34,195
+37% +$546K ﹤0.01% 1523
2025
Q2 		$1.02M Buy
+91,405
New +$804K ﹤0.01% 1844
2022
Q3 		– Sell
-17,045
Closed -$1.17M – 3613
2022
Q2 		$1.17M Buy
+17,045
New +$1.47M ﹤0.01% 2351
2022
Q1 		– Sell
-6,150
Closed -$1.02M – 3735
2021
Q4 		$1.02M Sell
6,150
-5,448
-47% -$866K ﹤0.01% 2461
2021
Q3 		$1.61M Buy
+11,598
New +$2.27M 0.01% 1699
2019
Q4 		– Sell
-3,242
Closed -$260K – 1923
2019
Q3 		$260K Sell
3,242
-19,093
-85% -$1.26M ﹤0.01% 1237
2019
Q2 		$1.44M Buy
22,335
+16,205
+264% +$1.54M 0.01% 854
2019
Q1 		$842K Buy
+6,130
New +$747K 0.01% 991

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Marshall Wace's MCRB Position: Q2 2026 in Review

Marshall Wace increased its Seres Therapeutics (MCRB) stake by 23% in Q2 2026, buying an estimated $249K and bringing the position to 172,245 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2052.

Marshall Wace first reported a position in MCRB in Q1 2019 and has held it in 11 quarters since. The position peaked at $2.42M in Q3 2025. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Marshall Wace held 172,245 shares of Seres Therapeutics worth $1.36M as of Q2 2026.
  • Marshall Wace bought 32,706 Seres Therapeutics shares in Q2 2026, an estimated $249K.
  • Seres Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2052 holding.
  • Marshall Wace first reported a position in Seres Therapeutics in Q1 2019 and has held it in 11 quarters since.
  • Marshall Wace's Seres Therapeutics position peaked at $2.42M in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.